Elsevier

Regulatory Peptides

Volume 17, Issue 1, January 1987, Pages 53-60
Regulatory Peptides

Atrial natriuretic peptide does not affect corticotropin-releasing factor-, arginine vasopressin- and angiotensin II-induced adrenocorticotropic hormone release in vivo or in vitro

https://doi.org/10.1016/0167-0115(87)90032-2Get rights and content

Abstract

The effect of synthetic atrial natriuretic peptide (ANP) was examined on the in vivo and in vitro release of ACTH. Intravenous ANP (4 μg/kg body weight) administration did not affect the corticotropin releasing factor (CRF, 4 μg/kg body weight)-, arginine vasopressin (AVP, 2 μg/kg body weight)- and angiotensin II (A II, 4 μg/kg body weight)-induced ACTH release in unanesthetized freely moving rats. ANP did not inhibit the basal, CRF- and AVP-induced release of ACTH in pituitary cell cultures. ANP did not affect the CRF- and AVP-induced plasma corticosterone elevation, while it attenuated the AVP-induced corticosterone elevation. These results indicate that ANP does not affect the ACTH release at the pituitary level in vivo and in vitro.

References (28)

  • A.A. Seymore et al.

    Renal and systemic effects of synthetic atrial natriuretic factor

    Life Sci.

    (1985)
  • K. Atarashi et al.

    Inhibition of aldosterone production by an atrial extract

    Science

    (1984)
  • L. Chartier et al.

    Atrial natriuretic factor inhibits the stimulation of aldosterone secretion by angiotensin II, ACTH and potassium in vitro and angiotensin II-induced steroidogenesis in vivo

    Endocrinology

    (1984)
  • A. De Lean et al.

    Specific receptor-mediated inhibition by synthetic atrial natriuretic factor of hormone-stimulated steroidogenesis in cultured bovine adrenal cells

    Endocrinology

    (1984)
  • Cited by (0)

    View full text